

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10595845	
	Filing Date		2006-05-16	
	First Named Inventor	Giancolotti		
	Art Unit	1644		
	Examiner Name	Maher M. Haddad		
Attorney Docket Number		MSK.P-076		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10595845
Filing Date		2006-05-16
First Named Inventor	Giancotti	
Art Unit	1644	
Examiner Name	Maher M. Haddad	
Attorney Docket Number	MSK P-076	

1	AVRAAMIDES et al. "Integrins in Angiogenesis and Lymphangiogenesis" Macmillan Publishers Limited, May 22, 2008, page(s) 1-14	<input type="checkbox"/>
2	BLOCH et al. "β1 Integrin Is Essential for Teratoma Growth and Angiogenesis" The Journal of Cell Biology, October 6, 1997, Page(s) 265-278, Volume 139, Number 1	<input type="checkbox"/>
3	BON et al. "Involvement of α6β4 Integrin in the Mechanisms that Regulate Breast Cancer Progression" Breast Cancer Research, February 23, 2007, Page(s) 1-5, Volume 9, Number 203	<input type="checkbox"/>
4	BROOKS et al. "Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin" The American Society for Clinical Investigation, Inc, October 1995, Page(s) 1815-1822, Volume 96	<input type="checkbox"/>
5	CARTER et al. "Distinct Functions for Integrins α3β1 in Focal Adhesions and α6β4/Bullous Pemphigoid Antigen in a New Stable Anchoring Contact (SAC) of Keratinocytes", The Journal of Cell Biology, Page(s) 3141-3154, Volume 111, Number 6	<input type="checkbox"/>
6	HYNES. "A reevaluation of integrins as regulators of angiogenesis" Nature Medicine, September 2002, Page(s) 918-921, Volume 8, Number 9	<input type="checkbox"/>
7	KIM et al. "Regulation of Angiogenesis in Vivo by Ligation of Integrin α5β1 with the Central Cell-Binding Domain of Fibronectin" American Journal of Pathology, December 21, 1999, Page(s) 1345-1362, Volume 156, Number 4	<input type="checkbox"/>
8	LEE et al. "Integrin Regulation by Vascular Endothelial Growth Factor in Human Brain Microvascular Endothelial Cells" The Journal of Biological Chemistry, August 7, 2006, Page(s) 40450-40460, Volume 281, Number 52	<input type="checkbox"/>
9	LEONG et al. "Integrin signaling: roles for the cytoplasmic tails of αIIbβ3 in the Tyrosine Phosphorylation of pp125FAK" Journal of Cell Science, 1995, Page(s) 3817-3825, Volume 108	<input type="checkbox"/>
10	MCCARTY et al. "Defective Associations between Blood Vessels and Brain Parenchyma Lead to Cerebral Hemorrhage in Mice Lacking αv Integrins" Molecular and Cellular Biology, November 2002, Page(s) 7667-7677, Volume 22, Number 21	<input type="checkbox"/>
11	MERDEK et al. "Intrinsic Signaling Functions of the β4 Integrin Intracellular Domain" The Journal of Biological Chemistry, October 2007, Page(s) 30322-30330, Volume 282, Number 41	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10595845
Filing Date		2006-05-16
First Named Inventor	Giancotti	
Art Unit	1644	
Examiner Name	Maher M. Haddad	
Attorney Docket Number	MSK P-076	

12	REYNOLDS et al. "Enhanced pathological angiogenesis in mice lacking $\beta 3$ integrin or $\beta 3$ and $\beta 5$ integrins" Nature Medicine, January 2002, Page(s) 27-34, Volume 8, Number 1	<input type="checkbox"/>
13	SENGER et al. "Angiogenesis promoted by vascular endothelial growth factor: Regulation through $\alpha 1\beta 1$ and $\alpha 2\beta 1$ Integrins", Proc.Natl. Acad. Sci, December 1997, Page(s) 13612-13617, Volume 94	<input type="checkbox"/>
14	SENGER et al. "The $\alpha 1\beta 1$ and $\alpha 2\beta 1$ Integrins Provide Critical Support for Vascular Endothelial Growth Factor Signaling, Endothelial Cell Migration, and Tumor Angiogenesis" American Journal of Pathology, January 2002, Page (s) 195-204, Volume 160	<input type="checkbox"/>
15	SERINI et al. "Integrins team up with tyrosine kinase receptors and plexins to control angiogenesis" Wolters Kluwer Health, 2008, Page(s) 235-242, Volume 15	<input type="checkbox"/>
16	SHAW et al. "Inside-out Integrin Signaling in Macrophages" The Journal of Biological Chemistry, 1993, Page(s) 11401-11408, Volume 268, Number 15	<input type="checkbox"/>
17	STEPHANS et al. "Deletion of beta 1 integrins in mice results in inner cell mass failure and peri-implantation lethality" Cold Spring Harbor Laboratory Press, 1995 Page(s) 1883-1895, Volume 9	<input type="checkbox"/>
18	STEPP et al. " $\alpha 6\beta 4$ integrin heterodimer is a component of hemidesmosomes" Proc. Natl. Acad. Sci. November 1990, Page(s) 8970-8974, Volume 87	<input type="checkbox"/>
19	WILHELMSEN et al. "Multiple Functions of the Integrin $\alpha 6\beta 4$ in Epidermal Homeostasis and Tumorigenesis" Molecular and Cellular Biology, April 2006, Page(s) 2877-2886, Volume 26, Number 8	<input type="checkbox"/>
20	ZHU et al. " $\beta 8$ Integrins are required for vascular morphogenesis in mouse embryos" The Company of Biologists Limited, 2002, Page(s) 2891-2903, Volume 129	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10595845
Filing Date	2006-05-16
First Named Inventor	Giancotti
Art Unit	1644
Examiner Name	Maher M. Haddad
Attorney Docket Number	MSK P-076

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10595845
Filing Date	2006-05-16
First Named Inventor	Giancotti
Art Unit	1644
Examiner Name	Maher M. Haddad
Attorney Docket Number	MSK P-076

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/marina/	Date (YYYY-MM-DD)	2008-08-05
Name/Print	Marina T. Larson, Ph.D.	Registration Number	32,038

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.